Phase 1/2a Trial: 36919 (T7-010-02)
This study, referred to as Phase 1/2a Trial 36919 (T7-010-02), is an early-phase clinical research trial open to adults between the ages of 18 and 65. It includes both men and women. At present, full details about the trial—such as the medical condition being researched and the specific treatment being tested—are not publicly available. This delay in publication has been approved by the UK Health Research Authority (HRA). Regulators sometimes allow this in early medical research to protect scientific or commercial confidentiality. All trial information, including the treatments used and the trial results, will be added to the public record within 30 months after the study ends. If you are looking for medical studies that might help your specific condition, your GP or hospital care team can help guide you toward active trials currently recruiting patients.
At a glance
What is this study about?
This clinical trial is listed as a Phase 1/2a study. Early-stage trials like this are usually the first steps in testing a potential new treatment in humans. Researchers typically run these studies to find out if a new medicine is safe, check what dose works best, and watch closely for any side effects. Because it is in the early stages, it only involves a relatively small number of people.
You might notice that key information about what this trial treats is missing. In the UK, the Health Research Authority (HRA) reviews and approves all clinical trials to protect patient safety. The HRA has formally agreed that the sponsor can wait to publish the full scientific details. This deferral is often granted to protect early scientific discoveries and commercial privacy while tests are ongoing.
Early research is vital because every approved medicine used in the NHS today began in trials just like this one. Even though the public record is limited right now, the study must still follow strict UK safety laws and ethical standards to protect anyone who takes part.
All details about the trial, its goals, and its findings will be published openly within 30 months after the study has finished. If you are interested in taking part in research, your doctor can advise you on what trials might be open and suitable for you.
Key takeaways
- This is an early-stage (Phase 1/2a) UK clinical trial open to adults aged 18 to 65.
- Full details about the condition and treatment are temporarily private under HRA approval.
- Complete trial details will be published within 30 months of the study finishing.
- Early trials focus closely on safety, correct dosages, and monitoring side effects.
- Joining any clinical trial is entirely optional, and you can stop at any time.
Who may be eligible?
The basic details released show that this trial is open to adults aged between 18 and 65 years old. Both men and women are eligible to take part.
Beyond age and sex, the detailed medical criteria—such as which health conditions you must have or what past treatments might rule you out—have not been made public yet. Early-stage trials may recruit either healthy volunteers or individuals living with a specific long-term condition, depending on the medicine being tested.
Because the full checklist is currently under a publication delay, doctors and research teams running the study will check eligibility directly with volunteers. If you are interested, a healthcare professional can help you explore whether you qualify for this trial or other similar research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You are aged between 18 and 65 years.
- You are interested in taking part in early medical research.
- You can travel to a UK research hospital or clinic for regular checks.
- You understand that specific medical requirements are not yet public.
- You are happy to speak to a doctor about whether this trial fits your health needs.
What does participation involve?
Because specific study details are deferred, the exact schedule of visits and treatments has not been published. However, taking part in an early-phase clinical trial generally involves an initial screening visit to check your general health, blood tests, and medical history. If accepted, participants receive the study treatment at a clinic or hospital and are monitored closely by doctors and nurses. You can expect regular follow-up appointments and health checks so the team can see how your body responds. The total time you would need to take part varies depending on the study design.
Potential risks and benefits
Locations (1)
- Simbec-Orion Clinical Pharmacology (AKA Simbec Research Ltd)UnverifiedMerthyr Tydfil, Wales
Common questions
Why are the study details kept secret?
The UK Health Research Authority (HRA) has allowed the study team to delay publishing full details to protect sensitive scientific or commercial information during early testing.
What does a Phase 1/2a trial mean?
It means the study is in its early stages. Researchers are primarily testing whether a new medicine is safe, looking for side effects, and seeing what dosage works best.
When will the full trial details be available?
The complete information and findings must be published on the study record within 30 months after the trial officially ends.
Can I sign up for this trial right now?
Because the full criteria are deferred, you cannot apply directly online. You should speak to your doctor or specialist to see if you can be connected to suitable open trials.
What happens if I join a trial and change my mind?
You can leave any clinical trial at any time, for any reason. Doing so will never harm or change the regular medical care you receive from the NHS.
How to find out more
Cynthia Cardinal
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.